Eye Catching Stock News: HTG Molecular Diagnostics (HTGM)

HTG Molecular Diagnostics (HTGM) changed -0.66% to recent value of $1.5. The stock transacted 207504 shares during most recent day however it has an average volume of 242.42K shares. It spotted trading -72.53% off 52-week high price. On the other end, the stock has been noted 4.17% away from the low price over the last 52-weeks.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, declared the release of its HTG EdgeSeqTM Reveal data analytics software, version 1.2.0. HTG EdgeSeq Reveal is a powerful software product that can enable customers to streamline their analysis of samples processed on the HTG EdgeSeq platform. The new release contains enhanced functionality enabling data analysis from the HTG EdgeSeq Precision Immuno‑Oncology Panel, the HTG EdgeSeq Oncology Biomarker Panel, and the newly released HTG EdgeSeq Mouse mRNA Tumor Response Panel. Together with HTG EdgeSeq molecular profiling assays, customers using the new HTG EdgeSeq Reveal software product will have the ability to more rapidly draw conclusions from their data and to generate charts representing their discoveries.

John Lubniewski, President and CEO of HTG said “Our customers asked for a powerful data analysis tool for use with our research use only (RUO) assays; we listened and delivered. HTG EdgeSeq Reveal allows our customers to quickly assess the quality and biological relevance of their data generated from our HTG EdgeSeq RUO assays,”. “With this new release, we have expanded the applications and utility of data analytics capabilities, including pathway assessment tools. Our innovative HTG EdgeSeq Reveal data analysis suite is a scalable, flexible data product that we believe will continue to expand with new assays and applications to support HTG’s growing product portfolio.”

 HTGM has a gross margin of 70.80% and an operating margin of -79.30% while its profit margin remained -80.00% for the last 12 months. Its earnings per share (EPS) expected to touch remained 66.60% for this year .

 The company has 29.34M of outstanding shares and 26.4M shares were floated in the market. According to the most recent quarter its current ratio was 6.3 that represents company’s ability to meet its current financial obligations. The price moved ahead of -17.06% from the mean of 20 days, -29.33% from mean of 50 days SMA and performed -46.11% from mean of 200 days price. Company’s performance for the week was -0.66%, -30.88% for month and YTD performance remained -40.94%.

Leave a Reply

Your email address will not be published. Required fields are marked *